Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
BETHESDA, Md., Nov. 02, 2016 -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces updates for five patents related to method and treatment of pain, seizures and eating disorders utilizing a combination of Phytocannabinoid Cannabidiol (CBD) and other compounds.
| Indication | Provisional Filing | PCT Filing | Subsequent Activity |
| Pain (Case 1) | 9/16/14 | 9/16/15 | US National Case Filed – 6/15/16 |
| Seizures (Case 2) | 6/15/15 | 6/14/16 | US National Case Filed – 6/15/16 |
| Seizures (Case 3) | 4/1/15 | 4/1/16 | PCT Application Published- 10/6/16 |
| Eating Disorders (Case 4) | 8/12/15 | 8/11/16 | US and National Filing Anticipated 2/12/18 |
| Seizures (Case 5) | 6/15/16 | Anticipated- 6/15/17 | US and National Filing Anticipated 12/15/18 |
Phytocannabinoids are chemical compounds that exert a range of effects on the human body, including impacting the immune response, gastrointestinal maintenance and motility, muscle functioning, and nervous system response and functioning. We have filed five provisional patents with the United States Patent and Trademark Office (“USPTO”), in the combination therapy space, for the indications of Pain, Medical Refractory Epilepsy and Cachexia as part of our intellectual property strategy focused on the phytocannabinoid based health care industry. The above table summarizes the latest corporate activities and it should be noted that there is no guarantee that filing a provisional or a non-provisional patent application will result in a successful registration with the USPTO.
As previously reported, approximately 50 million people worldwide are affected by Epilepsy (Sanders, 2003). Epilepsy is thought to be due to multiple factors that include Sodium, Potassium, GABA (gamma amino butyric acid) and NMDA (N-Methyl-d-aspartate). It is believed that to maximally control Epilepsy, modulation of one or more of these receptors is required and that mono therapy is adequate in up to 25% of patients.
The pain market represents a significant component of the healthcare system and The Journal of Pain in September 2012 reported that the annual estimated national cost of pain ranges from $560 billion to $635 billion. Additionally, The American Pain Society recommends that pain be made more visible and be categorized as the fifth vital sign.
Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. In the U.S. it is estimated that a population of approximately 1.3 million are experiencing Cachexia associated with Cancer, Multiple Sclerosis, Parkinson’s disease, HIV/AIDS and other progressive illnesses. Cancer induced Anorexia Cachexia is responsible for about 20% of all cancer deaths.
Mr. Ram Mukunda, CEO of IGC commented, “We see a significant opportunity in phytocannabinoid-based therapies and these additional filings further strengthen our current IP portfolio which encompasses the indications of Pain, Medical Refractory Epilepsy and Cachexia.”
About IGC
In the United States, we develop phytocannabinoid-based therapies. IGC has assembled a portfolio of patent filings that encompasses the indications of Pain, Medical Refractory Epilepsy and Cachexia using cannabinoids. We are based in Bethesda, Maryland.
Our website: www.igcinc.us. Twitter @IGCIR Facebook.com/IGCIR/
Contact: Claudia Grimaldi 301-983-0998
